ArticleBritish journal of haematology2025
Impact of age and time since diagnosis on thrombosis risk in myeloproliferative neoplasm patients: A nationwide register-based matched cohort study.
Article in British journal of haematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Evaluation of the frequency, risk factors, and outcomes of splanchnic vein thrombosis in myeloproliferative neoplasms: a retrospective cohort study.Journal of thrombosis and thrombolysis · 2026Article
- Impact of age and time since diagnosis on thrombosis risk in myeloproliferative neoplasm patients: A nationwide register-based matched cohort study.British journal of haematology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Thromboembolism is one of the major complications in myeloproliferative neoplasms (MPNs), especially in the initial years post-diagnosis and with increasing age. This nationwide matched cohort study used Swedish registers to assess whether attained age or time since diagnosis is more important for thrombosis risk. We identified 17 830 MPN patients diagnosed between 2001 and 2021, each matched with 10 population controls by sex, age and diagnosis year. Rates of first thrombosis post diagnosis and hazard ratios (HRs) were estimated using flexible parametric survival models over time since diagnosis and attained age. Thrombosis rates were significantly higher in MPN patients at all ages, especially in the first 2 years post-diagnosis, after which the rates remained higher than in age-matched controls. At 5 years, HR (95% confidence interval) for any thrombosis comparing patients to controls was 1.8 (1.7-1.9) at age 65, 1.6 (1.5-1.7) at age 70 and 1.5 (1.4-1.6) at age 75 and older. Attained age was more important than time since diagnosis, particularly in patients without prior thrombosis. Thrombosis rates were highest within the first 2 years post-diagnosis, then depended more on attained age than on time since diagnosis. These findings emphasize the importance of age and early management in MPN patients to optimize clinical care.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.